Pancreatic Cancer Debate: Optimal Therapy - Adjuvant FOLFIRINOX
Earn CME for related activities: https://www.naccme.com/oln
In this webcast from the 'Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability' symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Michael A. Choti argues in favor of utilizing adjuvant FOLFIRINOX for the treatment of pancreatic cancer.
© 2019 Imedex, an HMP Company
Видео Pancreatic Cancer Debate: Optimal Therapy - Adjuvant FOLFIRINOX канала HMP Education
In this webcast from the 'Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment Tolerability' symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Michael A. Choti argues in favor of utilizing adjuvant FOLFIRINOX for the treatment of pancreatic cancer.
© 2019 Imedex, an HMP Company
Видео Pancreatic Cancer Debate: Optimal Therapy - Adjuvant FOLFIRINOX канала HMP Education
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
The Patient Centered IBD Medical Home: Will This be the Future of IBD Healthcare Delivery?
Key Insights: Updates in Colorectal Cancer
Complex Clinical Cases: GI Bleeds
Key Insights: Novel Targets for IBD Therapy - Is This the Final Frontier?
Segment 2: Risk Assessment in Prostate Cancer
Mechanisms of Angiogenesis Inhibitors in Metastatic Colorectal Cancer
Virtual Patient Case: Carcinoid Syndrome #1 - Initial Presentation
Challenges Facing Medical Oncology Practice in the Next Decade
New agents/strategies on the horizon in bile duct cancer
What Determines “Quality” for Endoscopy Reporting in IBD Patients?
Optimizing Lumbar Discectomy: Closing Holes in the Disc
Expert Perspectives: MPN and MDS
Molecular Alterations and New Drugs in Bile Duct Cancer
Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP Inhibitors
Major Depressive Disorder: Leveraging the PCMH Model to Improve Patient-Centered Management
Multiple Myeloma Update: Maintenance Therapy
The Current Landscape of Biosimilars in IBD
Can We Increase the Immunogenicity in MSS CRC?
Optimizing Biological Therapies in the Modern Era
Key Insights in Chronic Lymphocytic Leukemia
Genetic Basis of Atypical Chronic Myeloid Leukemia (CML)